Genetic variants in key necroptosis regulators predict prognosis of non‐small cell lung cancer after surgical resection
暂无分享,去创建一个
E. Lee | Shin‐Yup Lee | J. Choi | S. Cha | I. Oh | J. Jeong | K. Shin | S. Yoo | Jaehee Lee | W. Lee | Hyo‐Gyoung Kang | M. Hong | S. K. Do | Y. Do | Jae-Yong Park | C. Kim | J. Lee | Young-chul Kim | Ji Eun Park | Y. Lee | Sunwoong Lee | S. Choi | H. Seo
[1] M. Mori,et al. Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study , 2022, JTCVS open.
[2] A. Chella,et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.
[3] D. Oh,et al. Necroptosis molecular mechanisms: Recent findings regarding novel necroptosis regulators , 2021, Experimental & Molecular Medicine.
[4] H. Stunnenberg,et al. The Role of Necroptosis: Biological Relevance and Its Involvement in Cancer , 2021, Cancers.
[5] Chuan-Qi Zhong,et al. RIP1-dependent linear and nonlinear recruitments of caspase-8 and RIP3 respectively to necrosome specify distinct cell death outcomes , 2021, Protein & cell.
[6] Hui Yu,et al. Bioinformatics analysis of differentially expressed miRNAs in non‐small cell lung cancer , 2020, Journal of clinical laboratory analysis.
[7] M. Tsuboi,et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.
[8] Susan M. Schlenner,et al. Necroptosis in Immuno-Oncology and Cancer Immunotherapy , 2020, Cells.
[9] E. Lee,et al. Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer , 2020, Journal of Cancer.
[10] L. Cai,et al. Single-nucleotide polymorphism rs17548629 in RIPK1 gene may be associated with lung cancer in a young and middle-aged Han Chinese population , 2020, Cancer Cell International.
[11] Zhangfeng Zhong,et al. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. , 2020, Cancer letters.
[12] Jun Hee Han,et al. Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection. , 2019, Annals of translational medicine.
[13] Chao Yang,et al. The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.
[14] D. Sharma,et al. Necroptosis: a regulated inflammatory mode of cell death , 2018, Journal of Neuroinflammation.
[15] Nicholas G Zaorsky,et al. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. , 2018, International journal of radiation oncology, biology, physics.
[16] M. Tsuboi,et al. Long‐term survival outcome after postoperative recurrence of non‐small‐cell lung cancer: who is ‘cured’ from postoperative recurrence? , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[17] Pei Zhang,et al. Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer , 2017, Technology in cancer research & treatment.
[18] Mi-bo Tang,et al. Necroptosis in neurodegenerative diseases: a potential therapeutic target , 2017, Cell Death and Disease.
[19] G. Brumatti,et al. Relevance of necroptosis in cancer , 2017, Immunology and cell biology.
[20] L. Zitvogel,et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy , 2016, Oncoimmunology.
[21] Sarah I. Alothman,et al. The Necrosome Promotes Pancreas Oncogenesis via CXCL1 and Mincle Induced Immune Suppression , 2016, Nature.
[22] A. Thorburn,et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics , 2015, Cell Research.
[23] P. Vandenabeele,et al. Necroptosis and its role in inflammation , 2015, Nature.
[24] Ling-gang Wu,et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis , 2013, Nature Cell Biology.
[25] W. Curran,et al. Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma , 2013, Cancer.
[26] L. Lang-Lazdunski. Surgery for nonsmall cell lung cancer , 2013, European Respiratory Review.
[27] Peter Vandenabeele,et al. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. , 2013, Immunity.
[28] Kenta Moriwaki,et al. The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis , 2012, Cell.
[29] Xiaodong Wang,et al. Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase , 2012, Cell.
[30] Guanghua Xiao,et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. , 2009, Cancer research.
[31] Eden R Martin,et al. No gene is an island: the flip-flop phenomenon. , 2007, American journal of human genetics.
[32] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[33] Frank C. Detterbeck,et al. The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.
[34] X. Wang,et al. Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. , 2015, Neoplasma.
[35] Ling He,et al. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. , 2013, OncoTargets and therapy.